Sage Therapeutics financials at a glance

+ Portfolio

The revenue of Sage Therapeutics is reported as 0.08646 billion Dollars in the fiscal year 2023. The earnings were -8.49 Dollars per share in 2023, which was 5.46 higher than 2022. And about -0.54114 billion Dollars are reported as free cash flow in the financials of Sage Therapeutics 2023. No dividends were paid to the shareholders of the Sage Therapeutics stock NasdaqGM:SAGE in the financial year 2023.

$86.46M

Revenue

$-8.49

Earnings Per Share

97.50%

Gross Margin %

$-,488.51M

Free Cash Flow

Revenue

86.46

Earnings Per Share

-8.49

Gross Margin %

97.50

Free Cash Flow

-,488.51

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Rev.	Revenue	N/A	$86.46M	$7.69M	$6.31M	$1.11B	$6.87M	$90.27M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	97.50%	0.00%	91.23%	73.68%	0.00%	-,212.50%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	56.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-10.98	$-8.49	$-8.98	$-7.80	$11.96	$-13.38	$-8.08	$-7.09	$-4.75	$-3.40	$-1.67
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	0.00%	-0.00%	-0.00%	-0.00%	-0.00%	0	0
Sha.	Shares	N/AM	60.11M	59.72M	59.05M	58.38M	51.91M	47.09M	45.78M	37.27M	32.02M	28.09M
OCF	Operating Cash Flow	N/A	$-,540.59M	$-,460.04M	$-,378.18M	$664.28M	$-,528.71M	$-,260.67M	$-,219.28M	$-,118.68M	$-70.68M	$-27.04M
FCF	Free Cash Flow	N/A	$-,488.51M	$-,460.97M	$-,378.55M	$660.83M	$-,534.46M	$-,263.53M	$-,220.64M	$-,120.10M	$-70.88M	$-27.17M
FCFS	Free Cash Flow Per Share	$-9.19	$-9.04	$-7.77	$-6.45	$12.77	$-10.51	$-5.71	$-5.79	$-3.59	$-2.55	$-1.26

Sage Therapeutics financials at a glance

Financials

Discover